Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil

Pediatric Blood and Cancer

Volumn 49, Issue 2, 2007, Pages 139-144

  Hsu, Saunders C ^a,e   Metzger, Monika L ^b   Hudson, Melissa M ^b   Pedrosa, Francisco ^c   Lins, Mecneide ^c   Pedrosa, Marcia ^c   Barros, Cynthia ^c   Maciel, Kaline ^c   Pui, Ching Hon ^b,d   Ribeiro, Raul C ^b   Howard, Scott C ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^d AMERICAN CANCER SOCIETY   (United States)

^e Division of Pediatric Hematology Oncology   (United States)

Author keywords

Hodgkin lymphoma; Low income country; Pediatric oncology

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; BRAZIL; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRAZIL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HOSPITALS, MATERNITY; HOSPITALS, PEDIATRIC; HOSPITALS, UNIVERSITY; HUMANS; INFANT; MALE; METHOTREXATE; OREGON; PREDNISONE; PROCARBAZINE; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TENNESSEE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 34447286917     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20883     Document Type: Article

References (22)

1. Masera G, Eden T, Schrappe M, et al. Statement by members of the Ponte di Legno group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:103-104.
2. International Society of Paediatric Oncology. Paediatric oncology in low income countries. The Montevideo Document. SIOP News; October 1995.
3. Magrath I. Pediatric oncology in countries with limited resources. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Phildelphia, PA: Lippincott Williams & Wilkins; 2002, pp 1541-1552.
4. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of total therapy studies 11, 12 and 13a for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.
5. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-2475.
6. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-1083.
7. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31: 1860-1861.
8. World development indicators. International Bank for Reconstruction and Development/the World Bank. Washington, DC; 2005.
9. Verner D. The dynamics of poverty and its determinants: The case of Pernambuco and the northeast of Brazil; 2000.
10. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 2002;20:3081-3087.
11. Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002;20:3088-3094.
12. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004;22:4541-4550.
13. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
16. Faria SL, Vassallo J, Cosset JM, et al. Childhood Hodgkin's disease in Campinas, Brazil. Med Pediatr Oncol 1996;26:90-94.
17. Gad-El-Mawla N, El-Deeb BB, Abu-Gabal A. et al. Pediatric Hodgkin's disease in Egypt. Cancer 1983;52:1129-1131.
18. Sagar TG, Chandra A, Raman SG. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report, Med Pediatr Oncol 2003;40:66-69.
19. Baez F, Ocampo E, Corner V, et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997;8:247-250.
20. Advani S, Pai S, Venzon D, et al. Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen. 1999;10:167-176.
21. Hesseling P, Robin B, Elizabeth M, et al. Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol 2003;41:532-540.
22. Wilimas JA, Ribeiro RC. Pediatric hematology-oncology outreach for developing countries. Hematol Oncol Clin North Am 2001;15: 775-787.